Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Australia
Wollongong Public, Wollongong, New South Wales Cancer Research SA, Adelaide, South Australia China
Chinese PLA General Hospital, Beijing, Beijing Municipality Shanghai East Hospital, Shanghai, Shanghai Municipality The First Affiliated Hospital of zhejiang University School of Medicine, Hangzhou, Zhejiang